Translating 10 Projects Weekly, Eli Lilly Launches Largest Acquisition Wave in Its History

Life Science

Beyond Lilly and Novo Nordisk: Two Under-the-Radar Picks in the Obesity Drug Market

Life Science

Is Pfizer’s Stock, with a Dividend Yield Exceeding 6%, Undervalued by the Market?

Life Science

These Three Disruptive Stocks Are Poised to Deliver Massive Returns Over the Next Two Decades

Life Science, Technology

Why Eli Lilly Is Underrated in the Red-Hot GLP-1 Weight-Loss Drug Race, per Morgan Stanley

Life Science

Strong Performance in Healthcare Sector Driven by Multiple Positive Factors

Life Science

Pfizer’s 50% Stock Crash: A Hidden Contrarian Buy Amid Booming Healthcare Sector

Life Science

Three Recession-Resistant Stocks Worth Investors’ Attention

Consumer Goods, Life Science

The Market Underestimates Bristol-Myers Squibb’s New Product Growth Potential

Life Science

Can Viking Therapeutics Replicate Eli Lilly’s Success in the Weight-Loss Drug Market?

Life Science

“Sell in May” Fails: Small Caps Could Be the Biggest Winner This Summer

Consumer Goods, Energy, Financial Service, Life Science

With the Macroeconomic Environment Improving, these Three Biotech Stocks Are Worth Watching

Life Science

CVS Health Stock Rallies 24% in a Month as Business Turnback Fuels Rebound

Financial Service, Life Science

Dyne Therapeutics Stock Rises 40% in a Year, but Saturn V Fund Reduces Holdings

Life Science

These Two Healthcare Giants Set for Fresh Dividend Hikes, Ideal Time to Invest

Life Science